Leadership Overview
Genentech has 10 executives leading key functions including strategy, operations, finance, technology, marketing, clinical development, and immunology research.
Committed to advancing medical science, Genentech delivers transformative biopharmaceutical therapies to address serious health conditions while maintaining a rigorous focus on patient-centered research and development.
Committed to advancing medical science, Genentech delivers transformative biopharmaceutical therapies to address serious health conditions while maintaining a rigorous focus on patient-centered research and development.
Leadership Roles at Genentech
Ashley Magargee - Chief Executive Officer
Ashley Magargee, the Chief Executive Officer at Genentech, directs the overarching strategic vision for the biotechnology enterprise. Magargee oversees the development of innovative therapies for serious medical conditions, ensuring alignment between research initiatives and long-term corporate objectives. By managing the executive leadership team, the Chief Executive Officer drives the organizational culture toward scientific excellence and operational efficiency. This leadership role involves navigating complex regulatory landscapes and fostering partnerships that expand the reach of biopharmaceutical solutions. Ashley Magargee maintains a focus on improving patient outcomes through the deployment of advanced medical technologies. Through the prioritization of high-impact research projects, the Chief Executive Officer secures the market position of the firm. Magargee evaluates performance metrics to ensure the company meets its ambitious goals for therapeutic innovation and sustainable growth within the global healthcare sector.
Luke Liu - Chief Financial Officer
Luke Liu, the Chief Financial Officer at Genentech, manages the fiscal health and capital allocation strategies of the biotechnology firm. Liu oversees financial planning, reporting, and investment analysis to support the research and development of innovative therapies. By directing the budgeting process, the Chief Financial Officer ensures that capital flows toward high-potential medical projects. This leadership role involves maintaining transparency with stakeholders and optimizing the cost structure of the organization. Luke Liu evaluates the financial viability of new drug candidates, providing the data necessary for informed decision-making at the executive level. Through the management of financial risk, the Chief Financial Officer protects the assets of the company. Liu drives long-term value creation by aligning fiscal policies with the broader mission of improving patient outcomes. The Chief Financial Officer maintains rigorous oversight of all monetary operations to ensure sustainable growth.
Matty Hackim - Chief Financial Officer, Solid Tumor Squad
Matty Hackim, the Chief Financial Officer, Solid Tumor Squad at Genentech, manages the financial strategy specifically for the oncology research division. Hackim oversees the allocation of resources for the development of therapies targeting solid tumors. By directing the financial planning for this specialized squad, the Chief Financial Officer, Solid Tumor Squad ensures that clinical trials receive the necessary funding to progress efficiently. This role involves analyzing the market potential of oncology treatments and providing insights to the broader executive team. Matty Hackim monitors the expenditure of research grants and operational budgets to maximize the impact of every dollar spent on cancer research. Through the optimization of financial processes, the Chief Financial Officer, Solid Tumor Squad supports the rapid advancement of life-saving oncology drugs. Hackim drives fiscal accountability within the squad, ensuring that all research activities align with the strategic goals of the company.
Roger Chylla - Chief Technology Officer
Roger Chylla, the Chief Technology Officer at Genentech, architects the digital and technical infrastructure required for advanced biopharmaceutical research. Chylla oversees the integration of data analytics and computational tools into the drug discovery process. By directing the technology roadmap, the Chief Technology Officer enables the rapid analysis of complex biological datasets. This role involves collaborating with research scientists to implement cutting-edge laboratory systems that accelerate therapeutic development. Roger Chylla manages the cybersecurity and information technology frameworks that protect proprietary research data. Through the deployment of scalable cloud solutions, the Chief Technology Officer enhances the operational capacity of the organization. Chylla drives innovation by identifying emerging technologies that improve the precision of medical treatments. The Chief Technology Officer ensures that the technical capabilities of the firm remain at the forefront of the biotechnology industry.
Ankita Chitre - Chief Marketing Officer & Head of Steriles, Quality (North America)
Ankita Chitre, the Chief Marketing Officer & Head of Steriles, Quality (North America) at Genentech, directs the commercial strategy and quality assurance protocols for the North American market. Chitre oversees the marketing campaigns that communicate the value of biopharmaceutical therapies to healthcare providers. By managing the quality standards for sterile products, the Chief Marketing Officer & Head of Steriles, Quality (North America) ensures that all medical solutions meet rigorous safety benchmarks. This role involves coordinating with regional sales teams to expand the market presence of the company. Ankita Chitre monitors the performance of product launches and adjusts commercial tactics to meet evolving patient needs. Through the integration of marketing and quality control, the Chief Marketing Officer & Head of Steriles, Quality (North America) maintains the reputation of the firm. Chitre drives growth by ensuring that high-quality therapies reach the patients who require them most.
Kara Teklinski - Global Product Development, Clinical Operations Chief of Staff (Pdg)
Kara Teklinski, the Global Product Development, Clinical Operations Chief of Staff (Pdg) at Genentech, coordinates the operational activities of the global clinical development division. Teklinski oversees the execution of clinical trials, ensuring that research protocols adhere to international standards. By directing the administrative functions of the clinical operations team, the Global Product Development, Clinical Operations Chief of Staff (Pdg) facilitates the smooth progression of drug development programs. This role involves managing communication between clinical researchers and executive leadership to ensure project alignment. Kara Teklinski monitors the progress of global trials, identifying bottlenecks and implementing solutions to maintain development timelines. Through the oversight of operational resources, the Global Product Development, Clinical Operations Chief of Staff (Pdg) supports the delivery of innovative therapies to the global market. Teklinski drives efficiency by streamlining the coordination of complex clinical research initiatives.
Neda Hamadani - Chief of Staff & Director, Immunology Commercial Portfolio
Neda Hamadani, the Chief of Staff & Director, Immunology Commercial Portfolio at Genentech, manages the strategic direction of the immunology product line. Hamadani oversees the commercialization efforts for therapies designed to treat immune-related conditions. By directing the portfolio strategy, the Chief of Staff & Director, Immunology Commercial Portfolio ensures that the company maintains a competitive edge in the immunology sector. This role involves analyzing market trends and coordinating with cross-functional teams to drive product adoption. Neda Hamadani monitors the performance of the immunology portfolio, providing guidance to the executive team on growth opportunities. Through the management of commercial initiatives, the Chief of Staff & Director, Immunology Commercial Portfolio supports the mission of improving patient outcomes. Hamadani drives the development of marketing strategies that highlight the efficacy of immunological treatments. The Chief of Staff & Director, Immunology Commercial Portfolio ensures that the immunology division remains a core pillar of the company.
Sneha Villivalam - Senior Business Manager & Global To Head of Translational Medicine Omni Chief of Staff
Sneha Villivalam, the Senior Business Manager & Global To Head of Translational Medicine Omni Chief of Staff at Genentech, manages the business operations for the translational medicine division. Villivalam oversees the integration of research findings into clinical practice, ensuring that scientific discoveries translate into viable medical solutions. By directing the administrative and strategic functions of the translational medicine team, the Senior Business Manager & Global To Head of Translational Medicine Omni Chief of Staff facilitates the rapid advancement of early-stage research. This role involves coordinating with global research heads to align project goals with corporate objectives. Sneha Villivalam monitors the allocation of resources for translational studies, ensuring that high-potential projects receive the necessary support. Through the management of business processes, the Senior Business Manager & Global To Head of Translational Medicine Omni Chief of Staff drives the efficiency of the research pipeline. Villivalam supports the mission of accelerating the development of innovative therapies.
Stefan Goshev - Strategy Lead & , Early Cancer Chief of Staff
Stefan Goshev, the Strategy Lead & , Early Cancer Chief of Staff at Genentech, directs the strategic planning for the early-stage oncology research division. Goshev oversees the identification of new opportunities in cancer research, ensuring that the company focuses on the most promising therapeutic targets. By managing the administrative and strategic operations of the early cancer team, the Strategy Lead & , Early Cancer Chief of Staff facilitates the transition of research concepts into clinical development. This role involves collaborating with scientific leaders to define the long-term vision for oncology innovation. Stefan Goshev monitors the progress of early-stage projects, providing the executive team with insights into the potential impact of new cancer therapies. Through the implementation of strategic frameworks, the Strategy Lead & , Early Cancer Chief of Staff drives the growth of the oncology portfolio. Goshev ensures that the research efforts of the company remain aligned with the goal of curing serious medical conditions.
Monica Brown - Deputy Director
Monica Brown, the Deputy Director at Genentech, manages critical operational workflows that support the research and development of biopharmaceuticals. Brown coordinates cross-functional teams to streamline the transition of therapies from laboratory settings to clinical application. Overseeing internal processes, the Deputy Director ensures that resource allocation aligns with the strategic priorities of the organization. This role requires constant collaboration with department heads to mitigate risks and optimize project timelines. Monica Brown monitors the execution of complex medical programs, ensuring adherence to quality standards and regulatory requirements. By facilitating communication across various research units, the Deputy Director enhances the efficiency of the development pipeline. Brown drives initiatives that improve the speed and accuracy of therapeutic discovery. Through the implementation of robust management frameworks, the Deputy Director supports the mission of delivering life-saving treatments to patients worldwide.
Explore Leadership Teams in Business Services
INVAP is a leading Argentine company with 50 years of experience in developing complex technological projects, particularly in nuclear technology, space, defense, and medical systems. They provide innovative solutions that enhance daily life, focusing on applications in health, environmental protection, and security. Their expertise allows them to manage the entire project lifecycle, catering to the needs of both public and private sectors. INVAP aims to improve the quality of life and contribute to sustainable development through their advanced technologies.
Company Leadership GS
GP
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham,...
Company Leadership FB
AS
Honeywell UOP, founded in 1914 and headquartered in Morris Plains, New Jersey, develops and commercializes technology for license to the oil refining, petrochemical, and gas processing industries.
Company Leadership LP
AT
BS
RT
GDM Seeds is a leading company in plant genetics for extensive crops, focusing on sustainable productivity and innovation. They research, develop, and commercialize products with intellectual property in plant genetics, aiming to expand geographically and diversify their crops. With 45% of the world's soybean production utilizing GDM genetics, they are committed to integrating cutting-edge technologies to enhance genetic gain and germplasm value. Their mission emphasizes fostering innovation, collaboration, and the development of new business opportunities that impact their core and the value chain.
Company Leadership Cd
CF
SD
Cd
Frequently Asked Questions Regarding Genentech Top Executives and Leadership Team
Unlock more people and company data
